Ocular Hypertension (OHT) Clinical Trials

Find Ocular Hypertension (OHT) Clinical Trials Near You

Longitudinal Observational Study Using Functional and Structural Optical Coherence Tomography to Diagnose and Guide Treatment of Glaucoma

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The specific aims of the clinical studies are to: * Develop a directional high-resolution OCT and OCT angiography prototype to improve imaging of structure and perfusion. * Validate wide-field OCT and OCT angiography parameters to improve early glaucoma detection. * Simulate visual field results by combining structural and angiography OCT data. * Assess abilities of above technologies and OCT-derived parameters on predicting glaucoma detection, conversion, and progression.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 85
Healthy Volunteers: t
View:

• No history or evidence of retinal pathology or glaucoma

• Normal Humphrey 24-2 VF: A mean defect (MD), corrected pattern standard deviation (CPSD) within 95% limits of normal reference, and glaucoma hemifield test (GHT) within normal limits (97%).

• Intraocular pressure \< 21 mm Hg

• Central corneal pachymetry \> 500 microns

• No chronic ocular or systemic corticosteroid use

• Open angle (gonioscopy must show 75% or more of the angle to be Grade 2 or more by Shaffer's grading system)

• Normal appearing ONH and NFL: vertical and horizontal cup/disc ratio (CDR) ≤ 0.5 and intact neuroretinal rim without peripapillary hemorrhages, notches, localized pallor, or NFL defect

• Symmetric ONH between left and right eyes: CDR difference \< 0.2 in both vertical and horizontal dimensions

• ONH or NFL defect visible on slit-lamp biomicroscopy defined as one of following:

‣ diffuse or localized thinning of the rim

⁃ disc (splinter) hemorrhage

⁃ notch in the rim

⁃ vertical cup/disc ratio greater than the fellow eye by \> 0.2

• Presence or absence of VF defects as measured by Humphrey SITA 24-2 VF.

Locations
United States
Oregon
Oregon Health & Science University, Casey Eye Institute
RECRUITING
Portland
Contact Information
Primary
Chinmay Deshpande, M.Optom.
deshpanc@ohsu.edu
503-494-9628
Backup
Denzil Romfh, OD
romfhd@ohsu.edu
503-494-4351
Time Frame
Start Date: 2013-09-25
Estimated Completion Date: 2026-05
Participants
Target number of participants: 160
Treatments
Glaucoma Group
Patients with clinically confirmed glaucomatous ONH or NFL defects, with or without VF abnormalities
Normal Group
Volunteers with healthy eyes
Related Therapeutic Areas
Sponsors
Collaborators: National Eye Institute (NEI)
Leads: Oregon Health and Science University

This content was sourced from clinicaltrials.gov